| International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study F Pagès, B Mlecnik, F Marliot, G Bindea, FS Ou, C Bifulco, A Lugli, ... The Lancet 391 (10135), 2128-2139, 2018 | 1831 | 2018 |
| Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours J Galon, B Mlecnik, G Bindea, HK Angell, A Berger, C Lagorce, A Lugli, ... The Journal of pathology 232 (2), 199-209, 2014 | 1488 | 2014 |
| Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. GJ Nabel, EG Nabel, ZY Yang, BA Fox, GE Plautz, X Gao, L Huang, S Shu, ... Proceedings of the National Academy of Sciences 90 (23), 11307-11311, 1993 | 1236 | 1993 |
| Cancer classification using the Immunoscore: a worldwide task force J Galon, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, A Berger, ... Journal of translational medicine 10 (1), 1-10, 2012 | 956 | 2012 |
| Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors T Duhen, R Duhen, R Montler, J Moses, T Moudgil, NF de Miranda, ... Nature communications 9 (1), 1-13, 2018 | 722 | 2018 |
| The immune score as a new possible approach for the classification of cancer J Galon, FM Marincola, M Thurin, G Trinchieri, BA Fox, TF Gajewski, ... Journal of translational medicine 10 (1), 1-4, 2012 | 603 | 2012 |
| OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer PatientsTargeting OX40 in Cancer Patients BD Curti, M Kovacsovics-Bankowski, N Morris, E Walker, L Chisholm, ... Cancer research 73 (24), 7189-7198, 2013 | 559 | 2013 |
| Cancer and inflammation: promise for biologic therapy S Demaria, E Pikarsky, M Karin, LM Coussens, YC Chen, EM El-Omar, ... Journal of immunotherapy 33 (4), 335-351, 2010 | 409 | 2010 |
| Granulocyte–macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non–small-cell lung cancer J Nemunaitis, D Sterman, D Jablons, JW Smith, B Fox, P Maples, ... Journal of the National Cancer Institute 96 (4), 326-331, 2004 | 320 | 2004 |
| Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy KH Young, JR Baird, T Savage, B Cottam, D Friedman, S Bambina, ... PloS one 11 (6), e0157164, 2016 | 304 | 2016 |
| Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40Timing Is Critical for OX40 plus PD-1 Combination DJ Messenheimer, SM Jensen, ME Afentoulis, KW Wegmann, Z Feng, ... Clinical Cancer Research 23 (20), 6165-6177, 2017 | 296 | 2017 |
| Neoantigen T-cell receptor gene therapy in pancreatic cancer R Leidner, N Sanjuan Silva, H Huang, D Sprott, C Zheng, YP Shih, ... New England Journal of Medicine 386 (22), 2112-2119, 2022 | 270 | 2022 |
| Novel technologies and emerging biomarkers for personalized cancer immunotherapy J Yuan, PS Hegde, R Clynes, PG Foukas, A Harari, TO Kleen, P Kvistborg, ... Journal for immunotherapy of cancer 4 (1), 1-25, 2016 | 265 | 2016 |
| Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer J Nemunaitis, T Jahan, H Ross, D Sterman, D Richards, B Fox, D Jablons, ... Cancer gene therapy 13 (6), 555-562, 2006 | 253 | 2006 |
| Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. AE Chang, A Aruga, MJ Cameron, VK Sondak, DP Normolle, BA Fox, ... Journal of clinical oncology 15 (2), 796-807, 1997 | 225 | 1997 |
| Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile HM Hu, WJ Urba, BA Fox The Journal of Immunology 161 (6), 3033-3041, 1998 | 199 | 1998 |
| Defining the critical hurdles in cancer immunotherapy BA Fox, DJ Schendel, LH Butterfield, S Aamdal, JP Allison, PA Ascierto, ... Journal of translational medicine 9 (1), 1-15, 2011 | 187 | 2011 |
| Immunotherapy of Malignancy by In Vivo Gene Transfer into Tumors GJ Nabel, A Chang, EG Nabel, G Plautz, BA Fox, L Huang, S Shu Human gene therapy 3 (4), 399-410, 1992 | 185 | 1992 |
| Signaling through OX40 enhances antitumor immunity SM Jensen, LD Maston, MJ Gough, CE Ruby, WL Redmond, M Crittenden, ... Seminars in oncology 37 (5), 524-532, 2010 | 173 | 2010 |
| Development of antitumor immune responses in reconstituted lymphopenic hosts HM Hu, CH Poehlein, WJ Urba, BA Fox Cancer research 62 (14), 3914-3919, 2002 | 171 | 2002 |
